Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
EyePoint Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative sustained-release therapeutics for serious retinal diseases. Its pipeline includes lead candidates like DURAVYU, a bioerodible intravitreal treatment for wet AMD and DME, utilizing proprietary drug delivery technology. The company also markets approved products such as DEXYCU and licenses others internationally, leveraging its expertise in ophthalmic drug delivery and targeted therapies.
This description was generated via AI from an annual report. Updated about 1 year ago.